LENZ Therapeutics (LENZ) Stock Price, Quote, News & History | Benzinga

LENZ Therapeutics Inc (LENZ) Stock Price, Quote, News & History

LENZNASDAQ

Trade with Public

Trade with Public

$5.80

0.5710.9%

At close: Sep 1, 5:00 PM EST

$5.80

0.5710.9%

Pre-Market: 8:03 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Dividends Compare Options Stock Report

Key Statistics

Open

-

Close

$5.80

Volume / Avg.

1.08K / 839.66K

Day Range

- - -

52 Wk Range

4.54 - 50.40

Market Cap

$182.24M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

65

Short Interest

58.61%

Days to Cover

12.53

Recent LENZ Therapeutics, Inc. News

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

LENZ Therapeutics partners with Arrotex to commercialize VIZZ in Australia and New Zealand as analysts remain focused on U.S. growth.

Vandana Singh

Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings

LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.

Avi Kapoor

New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug

FDA approved Tenpoint's Yuvezzi eye drop for presbyopia, adding competition for LENZ's VIZZ as analysts say the recent stock drop may be overdone and see blockbuster potential ahead.

Vandana Singh

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-113.91M

Investing Cash Flow (TTM)

-23.23M

Financing Cash Flow (TTM)

123.62M

Free Cash Flow (TTM)

-114.42M

Capital Expenditure (TTM)

-511.00K

Net Change in Cash (TTM)

-13.51M

Analyst Trends and Forecast

2

Mar

1

Apr

2

1

May

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$37.20M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8.26

PB Ratio (TTM)

0.83

Earnings Yield % (TTM)

-71.21%

Earnings Yield % (FWD)

-71.38%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$6.98

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$24.21M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$5.80

Volume / Avg.

1.08K / 839.66K

Day Range

- - -

52 Wk Range

4.54 - 50.40

Market Cap

$182.24M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

65

Short Interest

58.61%

Days to Cover

12.53

About

Sector

Health Care

Industry

Pharmaceuticals

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a onc...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy LENZ Therapeutics (LENZ) stock?

A

You can purchase shares of LENZ Therapeutics (NASDAQ:LENZ) through any online brokerage.

View our list of the best stock brokerages

Q

Who are LENZ Therapeutics (LENZ) competitors?

A

Other companies in LENZ Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for LENZ Therapeutics (LENZ) stock?

A

LENZ Therapeutics has a consensus price target of $30.29.

Q

What is the current price for LENZ Therapeutics (LENZ)?

A

The stock price for LENZ Therapeutics (NASDAQ: LENZ) is $5.8 last updated September 3, 2026 at 12:05 AM EDT.

Q

Does LENZ Therapeutics (LENZ) pay a dividend?

A

There are no upcoming dividends for LENZ Therapeutics.

Q

When is LENZ Therapeutics (NASDAQ:LENZ) reporting earnings?

A

LENZ Therapeutics does not have any upcoming earnings scheduled.

Q

Is LENZ Therapeutics (LENZ) going to split?

A

There is no upcoming split for LENZ Therapeutics.

Q

What sector and industry does LENZ Therapeutics (LENZ) operate in?

A

LENZ Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.